Rotavirus Vaccine Effectiveness Stratified By National-Level Characteristics: An Introduction to the 24-Country MNSSTER-V Project, 2007–2023
Open Access
- 28 November 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 232 (2) , 308-315
Abstract
Background: Rotavirus vaccines are moderately protective against illness in settings with high compared with low mortality rates. Vaccine effectiveness (VE) evaluations may clarify our understanding of these disparities, but estimates among key subpopulations and against rare outcomes are not available in many analyses due to sample size. We combined 25 data sets from test-negative design case-control evaluations in 24 countries that enrolled children with medically attended diarrhea, laboratory-confirmed rotavirus stool testing, and documented vaccination status. We calculated rotavirus VE stratified by country-level characteristics. Methods: Children 3–59 months old with birthdates and surveillance hospital arrival dates were included; other variables were standardized as available. Children were considered vaccinated if they received ≥1 dose of rotavirus vaccine >14 days before arrival. We summarized child- and country-level characteristics, including national <5-year-old mortality rate (U5M). Following the manufacturer recommended dose schedule, complete- and partial-series adjusted VE were estimated using logistic regression models. Results: We included 6626 rotavirus-positive children (case patients) and 19 459 rotavirus negative children (controls). Adjusted complete-series VE was significantly higher among children from countries in the low and medium U5M stratum (74% [95% confidence interval, 64%–81%]) compared with all groups within the high U5M stratum (range, 52% [42%–60%]) to 46% [31%–57%]). Partial-series estimates were lower than complete-series estimates. Conclusions: These findings are consistent with the published literature, though they suggest heterogeneity in vaccine performance within broad child mortality rate levels. Our findings also highlight the importance of complete-series vaccination.Keywords
This publication has 20 references indexed in Scilit:
- Test negative design for vaccine effectiveness estimation in the context of the COVID-19 pandemic: A systematic methodology reviewVaccine, 2023
- Real-world effectiveness of rotavirus vaccines, 2006–19: a literature review and meta-analysisThe Lancet Global Health, 2020
- Global impact of rotavirus vaccine introduction on rotavirus hospitalisations among children under 5 years of age, 2008–16: findings from the Global Rotavirus Surveillance NetworkThe Lancet Global Health, 2019
- Interventions to improve oral vaccine performance: a systematic review and meta-analysisThe Lancet Infectious Diseases, 2019
- Rotavirus vaccine effectiveness in low-income settings: An evaluation of the test-negative designVaccine, 2017
- Use of Patients With Diarrhea Who Test Negative for Rotavirus as Controls to Estimate Rotavirus Vaccine Effectiveness Through Case-Control StudiesClinical Infectious Diseases, 2016
- ggplot22016
- Individual participant data meta-analyses should not ignore clusteringJournal of Clinical Epidemiology, 2013
- Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trialThe Lancet, 2010
- Effect of Human Rotavirus Vaccine on Severe Diarrhea in African InfantsNew England Journal of Medicine, 2010